Kracov Quoted in Regulatory Affairs Professionals Society on FDA's RMAT Designation
May 9, 2017
Life Sciences and Healthcare Regulatory partner Daniel Kracov was quoted in a recent Regulatory Affairs Professionals Society article, "CBER Director Focuses on Flexibility to Advance Regenerative Medicines," which examines the FDA's regenerative medicine advanced therapy (RMAT) designation and its impact on expediting the development and approval of cutting edge cell and gene therapies.
